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Abstract
Background Pulmonary pulse wave velocity (PWV) allows the non-invasive measurement of pulmonary arterial stiffening, but
has not previously been assessed in COPD. The aim of the current study was to assess PWV in COPD and its association with
right ventricular (RV) remodelling.
Methods Fifty-eight participants with COPD underwent pulmonary function tests, 6-min walk test and cardiac MRI, while 21
healthy controls (HCs) underwent cardiacMRI. Thirty-two COPD patients underwent a follow-upMRI to assess for longitudinal
changes in RV metrics. Cardiac MRI was used to quantify RV mass, volumes and PWV. Differences in continuous variables
between the COPD and HC groups was tested using an independent t-test, and associations between PWVand right ventricular
parameters was examined using Pearson’s correlation coefficient.
Results Those with COPD had reduced pulsatility (COPD (mean±SD):24.88±8.84% vs. HC:30.55±11.28%, p=0.021), pulmo-
nary acceleration time (COPD:104.0±22.9ms vs. HC: 128.1±32.2ms, p<0.001), higher PWV (COPD:2.62±1.29ms-1 vs.
HC:1.78±0.72ms-1, p=0.001), lower RV end diastolic volume (COPD:53.6±11.1ml vs. HC:59.9±13.0ml, p=0.037) and RV
stroke volume (COPD:31.9±6.9ml/m2 vs. HC:37.1±6.2ml/m2, p=0.003) with no difference in mass (p=0.53). PWV was not
associated with right ventricular parameters.
Conclusions While pulmonary vascular remodelling is present in COPD, cardiac remodelling favours reduced filling rather than
increased afterload. Treatment of obstructive lung disease may have greater effect on cardiac function than treatment of pulmo-
nary vascular disease in most COPD patients
Key Points
• Pulmonary pulse wave velocity (PWV) is elevated in COPD.
• Pulmonary PWV is not associated with right ventricular remodelling.
• Right ventricular remodelling is more in keeping with that of reduced filling.
Keywords Magnetic resonance imaging .Pulmonaryarteries .Heartventricles .Pulse-waveanalysis .Pulmonarydisease,chronic
obstructive
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FVC Forced vital capacity
GOLD Global Initiative for Chronic Obstructive Lung
Disease
HR Heart rate
HC Healthy controls
ICS Inhaled corticosteroid
KCO Transfer factor for carbon monoxide
LABA Long-acting beta-agonist
LAMA Long-acting muscarinic antagonist
LV Left ventricle
LVEDV Left ventricle end-diastolic volume
LVEF Left ventricle ejection fraction
LVESV Left ventricle end-systolic volume
LVMVR Light ventricular mass to volume ratio
LVM Left ventricular mass
LVSV Left ventricle stroke volume
mMRC Modified British Medical Research Council
MPA Main pulmonary artery
MRI Magnetic resonance imaging
PA Pulmonary artery
PAT Pulmonary acceleration time
PC Phase contrast
PFTs Pulmonary function tests
PWV Pulse wave velocity
RLV Residual lung volume
RV Right ventricle
RVEDV Right ventricle end-diastolic volume
RVEF Right ventricle ejection fraction
RVESV Right ventricle end-systolic volume
RVH Right ventricular hypertrophy
RVM Right ventricular mass
RVMVR Right ventricular mass to volume ratio
RVSV Right ventricle stroke volume
SABA Short-acting beta-agonist
SAMA Short-acting muscarinic antagonist
SSFP Steady-state free precession
TE Time to echo
TLC Total lung capacity
TR Time to recovery
VENC Velocity encoding
Introduction
COPD is the second most common cause of pulmonary hy-
pertension after left-sided heart disease, with the prevalence of
this increasing with increasing severity of COPD [1]. In com-
parison to other causes of pulmonary hypertension, the pul-
monary pressure elevations are modest; however, survival is
poor and correlates better with the pulmonary pressures and
pulmonary vascular resistance than with the severity of air-
flow obstruction [2–5].
The role of pulmonary arterial stiffness in COPD was
highlighted in a recent study where an increase in pulmonary
arterial stiffness was observed during exercise with a greater
contribution from this to changes in the mean pulmonary ar-
terial pressures (mPAP) than the peripheral vascular resistance
(PVR) [6]. Pulmonary arterial wall thickness is also related to
exercise pulmonary pressures rather than resting pulmonary
pressures, and correlates highly with change in pressure from
rest to exercise [7]. This fits well with observations in idio-
pathic pulmonary hypertension where a curvilinear relation-
ship exists between RV function and PA distensibility. As a
result marked loss of pulmonary artery distensibility occurs
without commensurate loss of ventricular function until only
minimal distensibility remains when a rapid decompensation
of the right ventricle occurs [8]. Thus pulmonary arterial stiff-
ness may be a key early indicator of pulmonary vascular re-
modelling, and act as a biomarker for future dysfunction be-
fore significant adverse remodelling occurs [9].
To date the examination of pulmonary vascular stiffening
has been limited due to the need for right heart catheterisation.
However, advances inMRI technology have allowed the mea-
surement of pulmonary arterial pulse wave velocity – a direct
measure of pulmonary arterial stiffness, which does not re-
quire the knowledge of the underlying pulmonary pressures
to calculate [10]. Pulmonary PWV has been demonstrated to
be feasible, and to be increased in those with pulmonary hy-
pertension; however, it has never been used to examine the
pulmonary vasculature in COPD [11–14].
Thus, the aim of the current study was to examine pulmo-
nary arterial PWV in COPD and establish its association with
right ventricular remodelling with the hypothesis that: (1)
PWV would be elevated early in the disease process of
COPD and (2) that elevated PWV would be associated with
right ventricular hypertrophic remodelling.
Materials and methods
Between July 2014 and May 2016 participants were recruited
from a database of community spirometry readings, and di-
rectly from general practitioner surgeries, clinics and previous
research participants. Inclusion criteria for the study were a
diagnosis of COPD, based on the current Global Initiative for
Chronic Obstructive Lung Disease (GOLD) guidelines of
post-bronchodilator forced expiratory volume in 1 s (FEV1)/
forced vital capacity (FVC) <0.7 with a history of smoking;
and aged 40–85 years. Exclusion criteria were: History of
cardiac condition, including but not limited to ischaemic heart
disease, valvular disease (mild functional regurgitation
allowed), arrhythmia, cardiomyopathy, congestive cardiac
failure or congenital cardiac disease; previous cardiac or tho-
racic operation; other co-existent lung condition; connective
tissue disease or systemic vasculitis; severe renal impairment
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(estimated glomerular filtration rate (eGFR) < 30 ml/min) or
contraindication forMRI. All recruited participants underwent
a screening echocardiogram to exclude significant silent left
ventricular systolic dysfunction (ejection fraction < 45 %).
A healthy control (HC) group was recruited to be approx-
imately age and sex matched, with no prior history of cardiac
or pulmonary pathology. All participants gave written in-
formed written consent for the study, which was conducted
in accordance with the Declaration of Helsinki and was ap-
proved by the East of Scotland Research Ethics Committee 1.
All COPD participants underwent spirometry, DLCO,
body plethysmography, a 6-min walk test and a cardiac MRI
on the same day. A subset returned at 1 year after their baseline
visit for repeat cardiac MRI (CMR). All healthy controls
(HCs) underwent a baseline cardiac MRI. Plethysmography
and Diffusing Capacity of the Lungs for Carbon Monoxide
(DLCO) were performed using a VMax Encore V22 bodybox
(CareFusion, Basingstoke, UK). These were performed at rest,
prior to the 6-min walk test with a minimum of 24 h free from
inhaler therapy by dedicated pulmonary function laboratory
technicians following ERS/ATS guidelines [15]. The 6-min
walk test was performed as per ATS guidelines [16]. The only
deviation from these guidelines was the use of a 25-m straight-
line course as opposed to a 30-m course.
One hundred and four COPD participants were screened,
with 37 excluded due to co-existent coronary artery disease,
atrial fibrillation, prior thoracotomy, co-existent lung condi-
tion, left ventricular systolic dysfunction on echo or no history
of smoking. This left 67 in the cohort. Of these, 58 were
included in the final analysis (six excluded due to incomplete
scan secondary to claustrophobia, one due to a history ofmetal
fragments in the orbits not picked up in screening and two due
to inadequate image quality for analysis). All participants re-
cruited and scanned for the main study before August 2015
went on to have a 1-year follow-up scan. Of the 49 who were
scanned prior to this date, 35 underwent their follow-up ex-
amination. Sixteen were lost due to: pacemaker insertion
(n=1), lung cancer diagnosed on initial CMR and receiving
treatment for this (n=2), interval diagnosis of bladder cancer
(n=2), unwilling to undergone repeat CMR (n=1), recurrent
chest infections (as needed to be free from exacerbations for 2
months) (n=2), withdrawal from the study (n=2), and unable
to contact (n=6). Of the 35 scanned, onr had to be abandoned
due to claustrophobia despite having successfully completed
their CMR the preceding year, and two had images of insuf-
ficient quality to analyse, leaving 32 in the final follow-up
analysis.
MRI
Images were acquired with a 3T MR scanner (Prisma,
Siemens, Erlangen, Germany). A 32-element cardiac phase-
array was used for signal reception. For ventricular quantifi-
cation a balanced steady-state free precession (bSSFP) stack
was performed in breath-hold from the atrioventricular ring to
the apex using the following acquisition parameters: Slice
thickness 6 mm, interslice gap 4 mm, TR/TE 47.6/1.49 ms,
no. averages 1, phases 25, bandwidth/pixel 446 Hz, flip angle
53°, field of view (FOV) 360 × 360 mm2, FOV phase 84.4 %,
matrix 256 × 256, parallel acceleration factor 2. To plan the
main pulmonary artery phase contrast sequence, a bSSFP se-
quence of the right ventricular outflow tract was performed
following which an orthogonal plane was acquired to optimal-
ly visualise the main pulmonary artery and pulmonary valve.
A breath-hold bSSFP sequence was then performed through
the MPA slice and was positioned mid-way between the valve
and the bifurcation of the pulmonary artery in order to avoid
both structures throughout the cardiac cycle. A free-breathing
phase-contrast sequence (slice thickness 6 mm, TR/TE 12/4
ms, no. averages 1, phases 80, velocity encoding 150 cm/s,
bandwidth/pixel 340 Hz, flip angle 15°, field of view (FOV)
320×320 mm2, matrix 512×512) was then performed in the
same position as previously described [17].
Image analysis
Image analysis was performed using CVI 42 (Circle
Cardiovascular Imaging Inc., Calgary, Alberta, Canada).
Ventricular quantification Epicardial and endocardial con-
tours were drawn around the right ventricle at end-systole
and end-diastole. Trabeculae were included in the mass mea-
surement and excluded from the volume calculation due to
previous work showing that inclusion of the trabecular mass
improves correlation with pulmonary pressures and vascular
resistance [18]. The septum was treated as belonging to the
left ventricle and was excluded from the right ventricular
mass. Right ventricular mass and volumes were normalised
to height1.7. Twenty scans were analysed twice for reproduc-
ibility, with excellent reproducibility for all measures
(intraclass correlation (ICC) > 0.8 for all; see Supplementary
Material for full ICC (Table S1) and Bland-Altman analysis
(Fig. S1)).
Pulmonary stiffness Pulmonary stiffness was measured using
PWV, pulmonary acceleration time (PAT) and pulsatility (see
Fig. 1). For PWV, a contour was manually drawn around the
perimeter of the vessel on the magnitude image and then prop-
agated throughout the cardiac cycle and corrected when auto-
matic contouring led to erroneous boundaries. The program
then automatically calculated area, flow and velocity data,
which were exported to Excel 2010 (Microsoft, USA). The
area and flow were plotted against one another during early
systole, which was defined as the time period in systole during
which both the vessel area and flow were simultaneously
3466 Eur Radiol (2018) 28:3464–3472
increasing. The PWV was then calculated as described by
Davies et al. [19]:
PWV ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
∑ΔQ2
∑ΔA2
s
The reproducibility of this technique has been described in
detail previously [17, 20]. Pulmonary acceleration time (PAT)
was calculated as the time from first increase in the flow at the
start of systole to the point of maximum flow in systole using
the phase-contrast sequences. Pulmonary pulsatility was mea-
sured from a bSSFP short axis view of the pulmonary artery,
which was performed using the same acquisition parameters
as the ventricular analysis bSSFP sequences. Pulsatility was
calculated as [21]:
Pulsatility ¼ Maximum area−minumum area
Minimum area
 100
Statistics
The study was powered to examine the longitudinal effects
of PWV on right ventricular remodelling. Due to a lack of
prior work on the longitudinal follow-up of ventricular re-
modelling in COPD, the primary study outcome – change in
right ventricular mass – was powered according to the pla-
cebo arms of randomised control trials in pulmonary hyper-
tension as this was the only data available. These describe
an increase in mass of 5–8 g (change in right ventricular
mass detected over 4–36 months in groups of 21 and 44
participants, respectively) [22, 23]. Based on these factors,
n=17 would allow detection of a 4-g change with a study
power of 80 % and a p=0.05. Further work by Bradlow et al.
has shown a group size of 17 will allow detection of a 10-ml
change in RV end-diastolic volume, which correlates with
changes of 9–15 ml seen in the placebo arm of drug inter-
vention studies [22–24].
Descriptive statistics were used for the analysis of the de-
mographic and clinical features of the cohorts with data
expressed as mean ± SD. Normality and equality of variances
of the variables was tested. An independent sample t-test was
used to compare the differences in continuous variables be-
tween the HC and COPD cohort. To assess the longitudinal
impact of PWVon RV remodelling in COPD, this cohort was
divided into three according to the tertile of their baseline
PWV, and an independent sample t-test was used to compare
the difference in change in the RVmass and volumes between
those in the top and bottom tertiles of PWV. Chi-square and
Fisher’s exact tests were used as appropriate to compare dif-
ferences in ordinal and nominal data between the groups.
Pearson’s correlation coefficients were used to assess the cor-
relation between PWV and demographic, spirometric and
MRI factors. Analysis of covariance was performed to further
analyse differences in RV metrics and PWV between the HC
and COPD cohorts correcting for differences in baseline de-
mographics. Paired-sample t-tests were used to examine dif-
ferences in metrics between baseline and follow-up.
Reproducibility of measures was examined using a two-way
absolute agreement fixed effect ICC and Bland-Altman plots.
All data were analysed using SPSS statistical package (version
21.0, SPSS Inc. Chicago, IL, USA). Significance was as-
sumed when p < 0.05.
Results
Fifty-eight COPD patients (67.4±9.0 years old, 55 % male)
and 21 HCs (60.4±5.1 years old, 48 % male) completed the
study protocol. Despite approximate age and sex matching,
those with COPD were significantly older (p<0.001), had a
higher BMI (COPD: 26.8±5.2 kg/m2 vs. HC: 24.7±2.5 kg/m2,
Fig. 1 Calculation of pulse wave velocity, pulmonary acceleration time
and pulmonary pulsatility. Magnitude (A) and phase (B) images of the
main pulmonary artery from which flow (C) and area (D) data are
acquired from which the pulse wave velocity is derived. A zoomed in
period from early systole (E) demonstrates the calculation of the
pulmonary acceleration time (Δt). Cine images of the main pulmonary
artery at end diastole (F) and end systole (G) are used to calculate
pulmonary pulsatility
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p=0.02), and a higher resting heart rate (COPD: 73.8
±20.3 bpm vs. HC: 64.2±11.8 bpm, p=0.05). Of those with
COPD, the majority had moderate COPD, with n=12 with
GOLD I, n=32 with GOLD II, n=13 with GOLD III and
n=1 with GOLD IV COPD. Using the modified British
Medical Research Council (mMRC) breathlessness score
[25], experienced breathlessness was also on the milder end
of the spectrum, with n=5 grade 0, n=26 grade 1, n=14 grade
2, n=11 grade 3 and n=2 grade 4. Full baseline characteristics
are detailed in Table 1. The 32 who completed the follow-up
visit (mean age = 68.6±8.2 years, 50 % male) had a signifi-
cantly lower heart rate at baseline, but were otherwise no
different from the 26 who only underwent baseline imaging
(see Table S2).
Those with COPD demonstrated evidence of pulmonary
arterial stiffening and pulmonary vascular remodelling with
higher pulmonary artery area at end diastole (COPD: 2.36
±0.56 cm2/m1.7 vs. HC: 2.14±0.28 cm2/m1.7, p=0.027), reduced
pulsatility (COPD: 24.88±8.84 % vs. HC: 30.55±11.28 %,
p=0.021), reduced PAT (COPD: 104.0±22.9 ms vs. HC:
128.1±32.2 ms, p<0.001) and higher PWV (COPD: 2.62
±1.29 ms-1 vs. HC: 1.78±0.72 ms-1, p=0.001). Given that the
COPD cohort were older with a higher rate of smoking and a
higher BMI, an ANCOVAwas performed with PWVand these
variables. A small-to-moderate group effect size was seen be-
tween COPD and HCs for PWV, although this did not quite
reach significance (partial eta squared = 0.05, F=4.0, p=0.050)
(see Table S3). Compared with the HCs, those with COPD had
significantly smaller right ventricular end-diastolic volumes
(HC: 59.9±13.0ml/m1.7 vs. COPD: 53.6±11.1ml/m1.7,
p=0.037), stroke volume (HC: 37.1±6.2ml/m1.7 vs. COPD:
31.9±6.9ml/m1.7, p=0.003) (see Table 2 for full ventricular
and pulmonary arterial parameters). These between-group dif-
ferences persisted on ANCOVA analysis correcting for age,
BMI and smoking for RVEDV (F=4.6, p=0.035) and RVSV
(F=8.8, p=0.004) (see Table S3).
PWV was associated with BMI (R=-0.28, p=0.03) and di-
astolic blood pressure (R=0.35, p=0.009), and total lung ca-
pacity (R=0.28, p=0.039), with a trend towards an association
with residual volume (R=0.25, p=0.067), but did not demon-
strate any significant association with any right ventricular
parameters (see Table 3).
As the pulmonary stiffness did not appear to affect cardiac
remodelling and the cardiac remodelling appeared to be that of
a reduced preload (with reduced ventricular volumes) rather
than an increased afterload (which would be associated with
an increase in right ventricular mass) the determinants of the
cardiac volumes were examined as detailed in Table 4.
RVEDV and LVEDV demonstrated a strong correlation with
one another (R=0.64, p<0.001). Both RVEDV and LVEDV
demonstrated significant correlations with heart rate (RVEDV
R=-0.41, p=0.04; LVEDV R=-0.30, p=0.02) and DLCO
(RVEDV R=0.29, p=0.03; LVEDV R=0.28, p=0.03) and either
a trend or a significant correlation with KCO (RVEDV R=0.27,
p=0.046; LVEDV R=0.25, p=0.06) and BMI (RVEDV R=0.27,
p=0.04; LVEDV R=0.21, p=0.11).
At follow-up there was no significant change in right ven-
tricular mass or volumes (see Fig. 2 for changes in RVM and
Table S4 for full comparison of follow-up metrics). Those
with the stiffest arteries at baseline (upper tertile of PWV)
had no significant differences in right ventricular remodelling
Table 1 Demographics of the COPD and healthy control cohorts
Healthy controls COPD cohort p-value
N 21 58
Age (y) 60.4±5.1 67.5±9.2 <0.001
Sex (male) 10 (48 %) 30 (52 %) 0.75
BMI (kg/m2) 24.7±2.5 26.8±5.2 0.02
Heart rate (bpm) 64.2±11.8 73.8±20.3 0.05
Systolic BP (mm Hg) 127.6±13.9 131.1±20.0 0.47
Diastolic BP (mm Hg) 74.7±7.8 75.1±8.5 0.85
Smoking status
Current smoker 2 (10 %) 16 (28 %) <0.001
Ex-smoker 7 (33 %) 42 (72 %)
Never smoker 12 (57 %) 0 (0 %)
Pack years 4.68±7.4 48.5±24.0 <0.001
Medications
SABA 0 (0 %) 54 (93 %) <0.001*
SAMA 0 (0 %) 1 (2 %) 1.0*
LABA 0 (0 %) 8 (14 %) 0.10*
LAMA 0 (0 %) 36 (62 %) <0.001*
ICS 0 (0 %) 7 (12 %) 0.18*
LABA/ICS combo 0 (0 %) 28 (48 %) <0.001*
Oral steroid 2 (10 %) 4 (7 %) 0.65*
Antibiotics 0 (0 %) 2 (3 %) 1.0*
Theophylline 0 (0 %) 4 (7 %) 0.56*
Mucolytics 0 (0 %) 9 (16 %) 0.10*
GOLD status
I - 12 (21 %) -
II - 32 (55 %) -
III - 13 (22 %) -
IV - 1 (2 %) -
mMRC grade
0 - 5 (9 %) -
1 - 26 (45 %) -
2 - 14 (24 %) -
3 - 11 (19 %) -
4 - 2 (3 %) -
BMI bodymass index,BP blood pressure, SABA short-acting beta-agonist
, SAMA short-acting muscarinic antagonist, LABA long-acting ß-agonist,
LAMA long-acting muscarinic antagonist, ICS inhaled corticosteroid,
GOLD Global Initiative for Chronic Obstructive Lung Disease, mMRC
Modified British Medical Research Council
*Fisher’s exact test used for between-group analysis
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at follow-up than those with the most elastic arteries (bottom
tertile of PWV). For a full comparison of the change in ven-
tricular metrics between PWV tertiles see Table 5.
Discussion
COPD is associated with significant pulmonary arterial re-
modelling and stiffening; however, this stiffening is not asso-
ciated with adverse right ventricular remodelling.
This is the first study examining PWV in COPD, demon-
strating an elevated pulmonary PWV. The fact that an in-
creased PWV was accompanied by a fall in PAT and a fall in
the pulsatility provides further confirmatory evidence that sig-
nificant central pulmonary vascular remodelling is present
within the COPD cohort. In the current study we found that
while there was a significant elevation in PWV, this was not
associated with right ventricular hypertrophy.
In fact, despite the elevated arterial stiffness, the right ven-
tricular remodelling evident in our study was that of a reduced
preload rather than an increased afterload with evidence of
smaller right ventricular volumes, smaller stroke volume and
no significant increase in right ventricular mass. A similar
pattern was observed in a small study of 24 COPD patients
by Wells et al., where pulmonary arterial dilation was not
associated with any increase in right ventricular mass despite
being associated with a fall in right ventricular ejection frac-
tion [26]. In the current work, both right and left ventricular
volumes demonstrated a correlation with DLCO. It is well
established that severe emphysema is associated with reduced
cardiac volumes, thus our finding expands this observation of
a correlation between emphysema and reduced cardiac filling
into the milder end of the clinical spectrum [27]. This obser-
vation is also consistent with the findings of the MESA-
COPD cohort, which also showed reduced right ventricular
Table 3 Pearson’s correlation coefficients of pulse wave velocity
(PWV) with demographic, spirometric and right ventricular measures
PWV
Rho (95 % CI) p-value
Age 0.04 (-0.24–0.28) 0.75
BMI (kg/m2) -0.28 (-0.49–0.02) 0.03
Heart rate (bpm) 0.20 (-0.11–0.46) 0.14
Systolic BP (mm Hg) 0.14 (-0.18–0.45) 0.29
Diastolic BP (mm Hg) 0.35 (0.06–0.60) 0.009
SpO2 -0.06 (-0.40–0.27) 0.65
Pack years 0.01 (-0.24–0.26) 0.94
FEV1, % predicted -0.16 (-0.37–0.09) 0.24
FVC, % predicted -0.07 (-0.28–0.14) 0.61
FEV1/FVC -0.18 (-0.42–0.10) 0.18
FEF 25–75, % predicted -0.11 (-0.35–0.14) 0.40
DLCO, % predicted -0.05 (-0.28–0.27) 0.73
DLCO/VA, % predicted -0.07 (-0.33–0.26) 0.60
RLV, % predicted 0.25 (-0.03–0.47) 0.07
VC, % predicted -0.02 (-0.26–0.23) 0.88
TLC, % predicted 0.28 (0.00–0.51) 0.04
RLV /TLC 0.21 (-0.08–0.43) 0.13
6MWT (m) –0.17 (–0.39–0.07) 0.20
RVEDV (ml/m1.7) -0.12 (-0.36–0.18) 0.39
RVESV (ml/m1.7) -0.20 (-0.39–0.08) 0.14
RVSV (ml/m1.7) 0.02 (-0.22–0.28) 0.86
RVEF (%) 0.18 (-0.04–0.38) 0.18
RVM (g/m1.7) -0.24 (-0.49–0.02) 0.07
DLCO diffusing capacity of the lungs for carbon monoxide, FEF forced
expiratory flow, FEV1 forced expiratory volume in 1 s, FVC forced vital
capacity, PWV pulse wave velocity, PAT pulmonary acceleration time,
RVEDV right ventricular end-diastolic volume, RVESV right ventricular
end-systolic volume, RVSV right ventricular stroke volume, RVEF right
ventricular ejection fraction, RVM right ventricular mass, RLV residual
lung volume, TLC total lung capacity, VC vital capacity, 6MWT 6-min
walk test
Table 2 Ventricular quantification and measures of pulmonary arterial
stiffness and haemodynamics in the healthy control and COPD cohorts
Healthy controls COPD cohort p-value
N 21 58
Right ventricle
RVEDV (ml/m1.7) 59.9±13.0 53.6±11.1 0.04
RVESV (ml/m1.7) 22.9±8.6 21.8±7.3 0.58
RVSV (ml/m1.7) 37.1±6.2 31.9±6.9 0.003
RVEF (%) 63.0±7.9 59.8±7.8 0.10
RVM (g/m1.7) 15.1±3.2 16.3±3.4 0.53
RVMVR (g/ml) 0.27±0.04 0.31±0.06 0.004
Left ventricle
LVEDV (ml/m1.7) 59.9±9.9 56.1±12.0 0.17
LVESV (ml/m1.7) 23.9±6.4 23.3±9.3 0.77
LVSV (ml/m1.7) 35.9±5.0 32.9±6.7 0.06
LVEF (%) 60.5±6.0 59.3±8.6 0.57
LVM (g/m1.7) 41.4±7.5 43.4±9.4 0.37
Pulmonary artery
Max area (cm2/m1.7) 2.80±0.48 2.94±0.74 0.33
Min area (cm2/m1.7) 2.14±0.28 2.36±0.56 0.03
Pulsatility (%) 30.55±11.28 24.88±8.84 0.02
PAT (ms) 128.1±32.2 104.0±22.9 <0.001
PWV (ms-1) 1.78±0.72 2.62±1.29 0.001
LVEDV left ventricular end-diastolic volume, LVESV left ventricular end-
systolic volume, LVSV left ventricular stroke volume, LVEF left ventric-
ular ejection fraction, LVM left ventricular mass, PWV pulse wave veloc-
ity, PAT pulmonary acceleration time, RVEDV right ventricular end-
diastolic volume, RVESV right ventricular end-systolic volume, RVSV
right ventricular stroke volume, RVEF right ventricular ejection fraction,
RVM right ventricular mass, RVMVR right ventricular mass:volume ratio
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volumes with increasing emphysema burden as measured on
CT in a predominantly non-severe cohort with COPD [28].
Thus the current study adds to the current literature that in a
contemporary community population with COPD, the prima-
ry cardiac effects are those of emphysema induced preload
reduction rather than that of cor pulmonale [28, 29].
As both the MESA-COPD cohort and the current study
are predominantly within the milder spectrum of COPD,
further work is required to determine if, as the disease pro-
gresses into the very severe end of the spectrum, a shift
occurs from a preload driven phenotype into an afterload
driven phenotype. This is an important clinical consider-
ation as both require different management strategies with
the former benefiting from volume reduction strategies [30],
while the latter benefits from medications targeting the pul-
monary vasculature [31]. Further examination in a more
severe disease cohort is even more important as, if the same
right ventricular pattern of preload remodelling is still pres-
ent, it may provide a significant explanatory factor as to the
continued failure of traditional pulmonary hypertension
medications in a COPD cohort [32–35].
This is the first study to look at longitudinal changes in
ventricular function in COPD. Due to this lack of prior work,
the primary study outcome – change in right ventricular mass
– was powered according to the placebo arms of randomised
control trials in pulmonary hypertension. The rationale for this
was that all the cardiac MRI studies at the time of the study
design had described right ventricular hypertrophy, with the
severity of this increasing with COPD severity [36–39].
However, as we have seen, we found a pattern of reduced
ventricular volumes with no evidence of right ventricular hy-
pertrophy. Our observed right ventricular mass of 39 g is also
significantly lower than the mass of 74–102 g seen in the
Table 4 Correlation coefficients between right and left ventricular end-
diastolic volumes and demographic, spirometric and pulmonarymeasures
RVEDV LVEDV
r p r p
Age -0.05 0.69 -0.02 0.99
BMI (kg/m2) 0.27 0.04 0.21 0.11
Heart rate (bpm) -0.41 0.002 -0.30 0.02
Systolic BP (mm Hg) 0.02 0.90 0.14 0.31
Diastolic BP (mm Hg) -0.13 0.35 -0.07 0.63
SpO2 (%) -0.02 0.91 0.03 0.85
Pack years 0.11 0.41 0.05 0.69
FEV1, % predicted 0.22 0.09 0.18 0.17
FVC, % predicted 0.13 0.35 0.03 0.81
FEV1/FVC 0.21 0.12 -0.11 0.44
FEF 25–75, % predicted 0.23 0.08 0.23 0.08
DLCO, % predicted 0.29 0.03 0.28 0.03
KCO, % predicted 0.27 0.046 0.25 0.06
RLV, % predicted -0.21 0.12 -0.02 0.91
TLC, % predicted -0.23 0.10 0.12 0.38
VC, % predicted 0.11 0.44 0.21 0.12
RLV/TLC -0.20 0.15 -0.17 0.23
DLCO diffusing capacity of the lungs for carbon monoxide, FEF forced
expiratory flow, FEV1 forced expiratory volume in 1 s, FVC forced vital
capacity, PWV pulse wave velocity, PAT pulmonary acceleration time,
RLV residual lung volume, TLC total lung capacity, VC vital capacity,
6MWT 6-min walk test
Fig. 2 Bar (representing the mean) and dot (representing the individual
participants) plot of the change in right ventricular mass from baseline to
follow-up examination
Table 5 Comparison of the change in right ventricular measures at 1-
year follow-up across baseline pulse wave velocity (PWV) tertiles
Tertile p-value*
1 2 3
N 10 11 11
Baseline PWV 1.31±0.26 2.18±0.32 3.42±0.59
CMR
ΔRVEDV (ml/m1.7) -3.9±8.1 -1.6±7.0 1.3±8.9 0.18
ΔRVESV (ml/m1.7) -2.5±7.0 0.6±3.7 2.0±5.9 0.13
ΔRVSV (ml/m1.7) -1.3±5.6 -2.2±3.9 -0.5±5.9 0.75
ΔRVEF (%) 0.7±8.6 -2.2±3.3 -1.5±7.3 0.55
ΔRVM (g/m1.7) -0.66±2.8 0.26±4.2 0.53±2.3 0.29
ΔRVMVR (g/ml) 0.01±0.07 0.01±0.08 0.02±0.07 0.71
*p-value is tertile 3 (stiffest pulmonary arteries) compared to tertile 1
(most elastic pulmonary arteries)
PWV pulse wave velocity, RVEDV right ventricular end-diastolic volume,
RVESV right ventricular end-systolic volume, RVSV right ventricular
stroke volume, RVEF right ventricular ejection fraction, RVM right ven-
tricular mass, RVMVR right ventricular mass:volume ratio
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pulmonary hypertension interventional trials. Thus it is per-
haps not surprising that at 1-year follow-up we detected no
significant interval change in right ventricular mass. Given
that the change in absolute RV mass only equated to an in-
crease of 0.44 g, with a similarly small change in other ven-
tricular metrics, this suggests that cardiac remodelling occurs
slowly and can largely be considered stable over the usual
time period used in interventional studies. As a result, we
are unable to examine the longitudinal effects of pulmonary
PWVon ventricular remodelling other than to say that if it is
present it is likely small and beyond the power of this study to
detect it.
There are several limitations to the current study. As
previously mentioned, the current cohort were predomi-
nantly earlier stage COPD, although as this is the main
subtype seen in the community this more accurately
reflects the clinical environment rather than a study fo-
cussing on the severe end of the spectrum. Despite
attempted matching, the COPD cohort were older and
more obese, thus effects of these cannot be discounted.
A small effect of age on pulmonary PWV have been
previously described, but this is dwarfed by the 50 %
difference in PWV we observed between the two co-
horts, thus the effect is likely to be independent of this
confounder [40]. In comparison, no such literature exists
demonstrating an effect of obesity on pulmonary arterial
stiffness and we observed no association within this
cohort suggesting the bias of this confounder is limited.
The study used multiple pairwise comparisons, and thus
risk of type I error occurring has to be considered.
However, where p-values were borderline and would
have lost significance, the findings were congruent with
the available literature in areas such as in the ventricular
volumes. Finally, no invasive measures of pulmonary
pressure were performed. The PAT, known to correlate
well with mean pulmonary arterial pressure, was signif-
icantly lower in those with COPD, which would suggest
elevated pressures; however, future invasive studies may
be useful to evaluate the correlation between non-
invasive PWV and both rest and exercise induced pul-
monary hypertension in COPD.
While pulmonary vascular remodelling is present in
COPD, cardiac morphology and function favour reduced
preload rather than increased afterload. Treatment of ob-
structive lung disease may have greater effect on cardiac
function than treatment of pulmonary vascular disease in
most COPD patients.
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